Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorphentermine is a small molecule belonging to the amphetamine family, developed in 1962 as a serotonergic appetite suppressant. It functions primarily as a highly selective serotonin releasing agent (SRA) and was historically used for weight loss in individuals with overweightness or obesity. Despite being a relatively weak stimulant with low abuse potential, it was classified as a Schedule III controlled substance in the United States. The drug is no longer in use due to significant safety concerns, including its association with pulmonary hypertension and cardiac fibrosis, similar to other withdrawn serotonergic appetite suppressants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorphentermine.